Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Rathkopf DE, et al. Among authors: olmos d. Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.09.003. Online ahead of print. Eur Urol. 2024. PMID: 39317633 Free article.
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. Attard G, et al. Among authors: olmos d. Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667. Cancer Res. 2009. PMID: 19339269 Free article.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Reid AH, et al. Among authors: olmos d. J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159823 Free PMC article. Clinical Trial.
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS. Olmos D, et al. Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9. Lancet Oncol. 2012. PMID: 23059046 Free PMC article.
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J. Omlin A, et al. Among authors: olmos d. Eur Urol. 2013 Aug;64(2):300-6. doi: 10.1016/j.eururo.2012.12.029. Epub 2013 Jan 4. Eur Urol. 2013. PMID: 23313031
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G. Pezaro C, et al. Among authors: olmos d. Br J Cancer. 2013 Jul 23;109(2):325-31. doi: 10.1038/bjc.2013.340. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807167 Free PMC article. Clinical Trial.
192 results